Tianjin Lisheng Pharmaceutical Co.,Ltd.
Σύμβολο: 002393.SZ
SHZ
25.45
CNYΤιμή αγοράς σήμερα
12.3975
Λόγος P/E
7.8104
Δείκτης PEG
4.64B
MRK Cap
- 0.01%
DIV Απόδοση
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393-SZ) Οικονομικές καταστάσεις
Ισολογισμός
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 8384.27 | 2220.2 | 1993.6 | 1651.9 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 371.13 | 231.3 | 200.3 | -31.9 | ||||||||||||||||||
balance-sheet.row.net-receivables | 1996.79 | 321.5 | 427.7 | 461.9 | ||||||||||||||||||
balance-sheet.row.inventory | 779.47 | 176.3 | 199.1 | 228.8 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 449.96 | 100.5 | 4.9 | 13.9 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 11610.5 | 2818.5 | 2625.4 | 2356.4 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 4045.76 | 981.9 | 1029.8 | 1136.7 | ||||||||||||||||||
balance-sheet.row.goodwill | 57.92 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 567.45 | 124.9 | 135.5 | 144.2 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 625.37 | 124.9 | 135.5 | 144.2 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 6115.65 | 1810.6 | 1180.6 | 1531.8 | ||||||||||||||||||
balance-sheet.row.tax-assets | 134.98 | 39.5 | 33.7 | 16.3 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 177.12 | 5.3 | 286.1 | 5.5 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 11098.87 | 2962.1 | 2665.6 | 2834.5 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 22709.37 | 5780.6 | 5291 | 5190.9 | ||||||||||||||||||
balance-sheet.row.account-payables | 331.1 | 84.8 | 146.4 | 90.5 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 228.64 | 59.1 | 39.7 | 28.5 | ||||||||||||||||||
balance-sheet.row.tax-payables | 149.6 | 14.6 | 42.5 | 20.3 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 17.77 | 3.9 | 5.4 | 6.2 | ||||||||||||||||||
Deferred Revenue Non Current | 117.89 | 27.9 | 31.8 | 31.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 741.36 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 1093.6 | 467.4 | 543.9 | 1.4 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 906.67 | 223 | 211.7 | 228 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 17.77 | 3.9 | 5.4 | 6.2 | ||||||||||||||||||
balance-sheet.row.total-liab | 3750.51 | 849.2 | 941.7 | 780.4 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 736.51 | 184.3 | 184 | 182.5 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 5422.19 | 1393.7 | 1126.6 | 1098 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 9405.31 | 1612 | 1328.7 | 1439.4 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3334.68 | 1713.4 | 1710.1 | 1690.7 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 18898.68 | 4903.4 | 4349.4 | 4410.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 22709.37 | 5780.6 | 5291 | 5190.9 | ||||||||||||||||||
balance-sheet.row.minority-interest | 32.24 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-equity | 18930.92 | 4903.4 | 4349.4 | 4410.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 22709.37 | - | - | - | ||||||||||||||||||
Total Investments | 6486.78 | 2041.9 | 1380.9 | 1499.8 | ||||||||||||||||||
balance-sheet.row.total-debt | 246.41 | 63 | 45.1 | 34.7 | ||||||||||||||||||
balance-sheet.row.net-debt | -7705.06 | -1925.9 | -1748.2 | -1617.2 |
Κατάσταση ταμειακών ροών
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 374.48 | 361.8 | 93.6 | 122.1 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | -0.02 | 67.3 | 66.1 | 60.2 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -36.38 | -5.5 | -15.4 | -8.7 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 8.97 | -136.5 | 15.4 | 8.7 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 29.92 | 1.6 | 137.9 | 17.6 | ||||||||||||||||||
cash-flows.row.account-receivables | 17.52 | 17.5 | 25.1 | -19.5 | ||||||||||||||||||
cash-flows.row.inventory | 8.91 | 8.9 | 11.1 | -4.4 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -28.3 | 117 | 50.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 3.49 | 3.5 | -15.4 | -8.7 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | -128.58 | -79.3 | 33.8 | -3.6 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 245.52 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -59.66 | -61.7 | -40.9 | -88.2 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 147.74 | 151.5 | 115.3 | 0.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -580 | -470 | -320 | -70 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 339.7 | 390 | 90 | 82 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 31.53 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -120.69 | 9.9 | -155.6 | -76.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | -22.45 | 0 | -0.1 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -6.29 | -54.7 | -54.7 | -18.2 | ||||||||||||||||||
cash-flows.row.other-financing-activites | -65.85 | 5.9 | 21 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -143.04 | -48.8 | -33.8 | -18.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 30.37 | 25.1 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | -7.46 | 195.7 | 142 | 102 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 7910.84 | 1989 | 1769.6 | 1627.7 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7918.29 | 1793.3 | 1627.7 | 1525.7 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 245.52 | 209.5 | 331.4 | 196.3 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -59.66 | -61.7 | -40.9 | -88.2 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 185.86 | 147.8 | 290.5 | 108.1 |
Σειρά κατάστασης λογαριασμού αποτελεσμάτων
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1170.61 | 1130.2 | 1146.6 | 1091.9 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 515.47 | 495.6 | 486.3 | 454.5 | ||||||||||||||||||
income-statement-row.row.gross-profit | 655.14 | 634.5 | 660.3 | 637.5 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 103.47 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 24.94 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 314.2 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -29.02 | -13.8 | 108.4 | 96.1 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 564.73 | 521.9 | 576.8 | 591.8 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1080.2 | 1017.5 | 1063.1 | 1046.3 | ||||||||||||||||||
income-statement-row.row.interest-income | -29.87 | 61.2 | 68.3 | 87.6 | ||||||||||||||||||
income-statement-row.row.interest-expense | 1.54 | 0.9 | 0.9 | 0.3 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 314.2 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 49.9 | 296.6 | -57.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -29.02 | -13.8 | 108.4 | 96.1 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 49.9 | 296.6 | -57.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 1.54 | 0.9 | 0.9 | 0.3 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | -194.14 | 67.3 | 66.1 | 75.8 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 175.88 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 370.02 | 112.6 | 175.7 | 136.9 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 419.92 | 409.2 | 118.4 | 137.1 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 57.56 | 58.4 | 24.8 | 15 | ||||||||||||||||||
income-statement-row.row.net-income | 374.48 | 361.8 | 93.6 | 122.1 |
Συχνές ερωτήσεις
Ποιο είναι το Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) το σύνολο του ενεργητικού?
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) το συνολικό ενεργητικό είναι 5780604152.000.
Ποια είναι τα ετήσια έσοδα της επιχείρησης?
Τα ετήσια έσοδα είναι 594641936.000.
Ποιο είναι το περιθώριο κέρδους της επιχείρησης?
Το περιθώριο κέρδους της επιχείρησης είναι 0.560.
Ποια είναι η ελεύθερη ταμειακή ροή της επιχείρησης?
Η ελεύθερη ταμειακή ροή είναι 1.019.
Ποιο είναι το καθαρό περιθώριο κέρδους της επιχείρησης?
Το καθαρό περιθώριο κέρδους είναι 0.320.
Ποια είναι τα συνολικά έσοδα της επιχείρησης?
Τα συνολικά έσοδα είναι 0.316.
Ποια είναι η Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) καθαρό κέρδος (καθαρό εισόδημα)?
Το καθαρό κέρδος (καθαρό εισόδημα) είναι 361827990.000.
Ποιο είναι το συνολικό χρέος της επιχείρησης?
Το συνολικό χρέος είναι 63035414.000.
Ποιος είναι ο αριθμός των λειτουργικών εξόδων?
Τα λειτουργικά έξοδα είναι 521915434.000.
Ποιος είναι ο αριθμός των ταμειακών διαθεσίμων της εταιρείας?
Τα ταμειακά διαθέσιμα της επιχείρησης είναι 1952585069.000.